Concepedia

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, G.J. Veldhuis, Rogier Mous, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Johan A. Dobber,

The Lancet Oncology · 2022 · 58 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

, , +14

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2018 · 1.7K citations · Full text

, , +5

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

, , +17

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

, , +4

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

, , +13